Show simple item record

dc.contributor.authorFoy, Robbie
dc.contributor.authorSo, June
dc.contributor.authorRous, Elizabeth
dc.contributor.authorScarffe, J Howard
dc.date.accessioned2009-12-15T16:08:51Z
dc.date.available2009-12-15T16:08:51Z
dc.date.issued1999-02-13
dc.identifier.citationPerspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold. 1999, 318 (7181):456-9 BMJen
dc.identifier.issn0959-8138
dc.identifier.pmid9974468
dc.identifier.urihttp://hdl.handle.net/10541/88031
dc.language.isoenen
dc.subject.meshAmbulatory Care
dc.subject.meshAntineoplastic Agents
dc.subject.meshCancer Care Facilities
dc.subject.meshDrug Costs
dc.subject.meshEvidence-Based Medicine
dc.subject.meshFeedback
dc.subject.meshGreat Britain
dc.subject.meshHealth Priorities
dc.subject.meshHospitalization
dc.subject.meshHumans
dc.subject.meshMedical Oncology
dc.subject.meshOutcome Assessment (Health Care)
dc.titlePerspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold.en
dc.typeArticleen
dc.contributor.departmentStockport Health Authority, Stockport SK7 5BY. R.Foy@ed.ac.uken
dc.identifier.journalBMJen


This item appears in the following Collection(s)

Show simple item record